Health Care/Hospital
WuXi XDC and Celltrion Sign MOU for Integrated Services for Antibody-Drug Conjugates (ADCs)
SHANGHAI and INCHEON, South Korea, Jan. 23, 2024 /PRNewswire/ -- WuXi XDC(2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market, and Celltrion, Inc. (068270.KS), a leading global biopharmaceutical...
2024-01-24 11:37
1159
PharmAbcine Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors
* Initiation of Phase 1a/b clinical trial exploring MTD, RP2D, safety and tolerability of PMC-309 monotherapy and combination therapy with KEYTRUDA® * The clinical trial aims to enroll a total of 67 patients across four institutions inAustralia DAEJEON, South Korea, Jan. 23, 2024 /PRNewswire/ ...
2024-01-24 10:01
1072
Datasea Pre-Announces First Half 2024 Revenue of $18.2 Million, a 1,037.5% Year-Over-Year Increase
BEIJING, Jan. 23, 2024 /PRNewswire/ -- Datasea Inc., (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada incorporated digital technology corporation engaged in converging and innovative business segments for intelligent acoustics and 5G messaging technology inChina pre-announced that its revenue...
2024-01-23 22:35
3003
Rhino Rescue Speeds into the Future of First-Aid Supplies with New Year Resolutions for 2024
Propelling Lifesaving Measures with User-friendly Innovations in 2024
SHANGHAI, Jan. 23, 2024 /PRNewswire/ -- As the New Year unfolds, Rhino Rescue
2024-01-23 22:15
1459
Akeso Presented Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI
HONG KONG, Jan. 23, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso," "we," or the "Company") today announced that the Company presented the promising phase II results of cadonilimab (a tetravalent PD-1/CTLA-4 bispecific antibody) and Lenvatinib (Len) combined with TACE for the treatment of mi...
2024-01-23 21:00
2847
Caliway Received First Approval of CBL-514 Pivotal Phase 3 Study Application for Subcutaneous Fat Reduction
NEW TAIPEI CITY, Jan. 23, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announces that Australian Bellberry HREC has approved Caliway's application to initiate CBL-514's Pivotal Phase 3 study (CBL-0301 Phase 3) for subcutaneous fat reduction. "We are all delighted to see CBL-514 show...
2024-01-23 18:35
1056
Baird Medical Performs First Thyroid Microwave Ablation Procedure in the United States
FRISCO, Texas, Jan. 23, 2024 /PRNewswire/ -- Baird Medical Devices, Inc. ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider inChina and the United States, today announced that it has performed its first thyroid MWA procedure inthe United...
2024-01-23 18:00
1107
European Medicines Agency (EMA) Grants Orphan Drug Designation (ODD) to GC Biopharma's Treatment for Sanfilippo Syndrome (Type A)
YONGIN, South Korea, Jan. 22, 2024 /PRNewswire/ -- GC Biopharma Corp. (006280.KS) announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to its intracerebroventricular (ICV) Enzyme Replacement Therapy (ERT) candidate, GC1130A, designed for Sanfilippo Syndrome...
2024-01-23 11:53
1249
36,000 units of MAIDeSITe Electric Floor Lift have been sold on Amazon
HANGZHOU, China, Jan. 22, 2024 /PRNewswire/ --
The MAIDeSITe Electric Floor Lift
2024-01-23 10:59
977
UHS deploys Cutting-Edge Robotic Cleaning Technology developed by CenoBots
AUSTIN, Texas, Jan. 22, 2024 /PRNewswire/ -- CenoBots is excited to announce its partnership with UHS fromSan Antonio, a valued hospital system partner, for deploying cleaning robots. The deployment is also being carried out in collaboration with Hellogard Robotics. This collaboration serves as a...
2024-01-22 21:00
1062
NK CellTech Announces FDA Clearance for Clinical Trial of NK010
SHANGHAI, Jan. 22, 2024 /PRNewswire/ -- On January 17, 2024, NK CellTech Co., Ltd. (NK CellTech), a leading biotech company focused on the development of NK cellular therapies, is pleased to announce that the FDA has granted clearance for the clinical trial of NK010, the non-genetically modified ...
2024-01-22 20:10
1318
Sanyou Super Trillion Peptide Molecule Discovery Platform Officially Launched Today
SHANGHAI, Jan. 19, 2024 /PRNewswire/ -- On January 13, 2024 local time, Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. officially announced the launch of its "Sanyou Super Trillion Peptide Molecule Discovery Platform". The Sanyou Super Trillion Peptide Molecule Discovery Platform is an integral ...
2024-01-20 08:00
2304
Jacobio Pharma Presents Data of Glecirasib in Patients with Pancreatic Cancer and Other Solid Tumors at the 2024 ASCO GI
BEIJING and SAN FRANCISCO, Jan. 19, 2024 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK), a clinical-stage oncology company focusing on undruggable targets, announced data of glecirasib in patients with pancreatic cancer and other solid tumors in the oral abstract session at the American Socie...
2024-01-20 06:30
2371
Datasea Enters into Agreement with U.S. Marketing Firm to Promote and Market its Innovative Intelligent Acoustics Products
The Agreement is Expected to Expand DTSS' Footprint in the U.S. and Increase Product Sales BEIJING, Jan. 19, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), which engages in the business segments of U.S.-based intelligent acoustics andChina-based 5G messaging techn...
2024-01-19 22:00
1682
CARsgen's Presents Updated Research Results on CT041 at 2024 ASCO GI Meeting
SHANGHAI, Jan. 19, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the 2024 American Society of Clinical Oncology Gastrointestin...
2024-01-19 21:50
1584
Harbour BioMed Announces Positive Profit Alert
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Jan. 18, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunol...
2024-01-19 12:52
5023
Datasea Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement
BEIJING, Jan. 18, 2024 /PRNewswire/ -- Datasea Inc., a Nevada corporation (NASDAQ: DTSS) ("Datasea" or the "Company"), which engages in the business segments of U.S.-based intelligent acoustics andChina-based 5G messaging technology, today announced that the Company's Board of Directors has appro...
2024-01-19 05:39
3588
FDA CLEARANCE OF AMPLIA'S IND FOR PANCREATIC CANCER TRIAL IN US
HIGHLIGHTS * The US FDA has cleared Amplia's Investigational New Drug (IND) Application for a clinical trial of narmafotinib in theUSA * The proposed trial would explore the combination of narmafotinib and FOLFIRINOX in advanced pancreatic cancer patients in theUSA MELBOURNE, Australia ,Jan. ...
2024-01-18 10:31
1180
Lunit INSIGHT CXR Excels in Lung Nodule Detection - Exceptional Performance in Head-to-Head Study published in Radiology
- Lunit's AI-powered chest X-ray analysis solution shows highest AUC of 0.93 in a recent multi-center, multi-use case, multi-vendor lung nodule detection study SEOUL, South Korea, Jan. 17, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostic...
2024-01-17 22:15
1395
Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia (CML) Management from the National Comprehensive Cancer Network (NCCN)
SUZHOU, China, and ROCKVILLE, Md., Jan. 16, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that olverembatinib (R&D Code: HQP1351) has been ...
2024-01-17 12:10
3795
Week's Top Stories
Most Reposted
Troy Animal Healthcare Strengthens Quality Operations with Veeva Vault Quality
[Picked up by 321 media titles]
2024-05-17 07:00Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
[Picked up by 319 media titles]
2024-05-15 12:00
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
[Picked up by 303 media titles]
2024-05-16 15:00
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
[Picked up by 274 media titles]
2024-05-16 09:39
Trip.com Group and Rezdy Join Forces to Offer New Travel Experiences Around the World
[Picked up by 229 media titles]
2024-05-14 18:07Most Read
Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
2024-05-15 12:00
8658
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
2024-05-16 15:00
6883
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
2024-05-16 09:39
6571
Traveloka strengthens sustainability pledge as world's first Platinum Sponsor of GSTC
2024-05-13 16:42
6551
Casio to Release G-SHOCK-Surfrider Foundation Collaboration
2024-05-15 09:00
6439
